
Please try another search
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Robert L. Erwin | 72 | 2008 | Member of Scientific Advisory Board |
Timothy Blackwell | - | 2014 | Member of Clinical Advisory Board |
Thomas A. Medsger | - | 2014 | Member of Clinical Advisory Board |
Alexandra Kropotova | 53 | 2020 | Independent Director |
Richard M. Silver | - | 2014 | Member of Clinical Advisory Board |
Gary L. Sender | 63 | 2020 | Lead Independent Director |
Martin B. Brenner | 55 | 2021 | CEO, Chief Scientific Officer & Director |
J. Terrill Huggins | - | 2014 | Member of Clinical Advisory Board |
Evert B. Schimmelpennink | 53 | 2019 | Independent Director |
William D. Clark | 56 | 2021 | Independent Chairman |
Antonio Parada | 57 | 2024 | Independent Director |
David A. Arkowitz | 64 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review